Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

NCT03031483 is registered in ClinicalTrials.gov with International Extranodal Lymphoma Study Group (IELSG) as lead sponsor.

NCT NCT03031483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03031483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma
Lead sponsor
International Extranodal Lymphoma Study Group (IELSG)
Phase
Phase 2
Overall status
Completed
Start date
April 3, 2017
Completion date
December 20, 2024
Enrollment
44 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

mucosa associated lymphoid tissue (malt) lymphoma